Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics (NQ: CRDL )

2.010 -0.020 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 91,932
Open 2.020
Bid (Size) 1.840 (12)
Ask (Size) 2.020 (2)
Prev. Close 2.030
Today's Range 1.920 - 2.025
52wk Range 0.6610 - 3.120
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
Via TheNewswire.com
Exposures Product Safety
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients 
Via News Direct
Exposures Product Safety

Performance

YTD
+128.41%
+128.41%
1 Month
-0.99%
-0.99%
3 Month
-6.07%
-6.07%
6 Month
+89.62%
+89.62%
1 Year
+111.58%
+111.58%

More News

Read More
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Exposures Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via TheNewswire.com
Topics ETFs
Exposures Product Safety
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
Via AB Newswire
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Via News Direct
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
Via InvestorPlace
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Via Benzinga
Topics Cannabis
Exposures Cannabis
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Via Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Via Newsfile
Exposures Product Safety
Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite
Via Talk Markets
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Via Newsfile
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Via Get News
Topics Death
Exposures Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Via News Direct
Topics Death
Exposures Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Via TheNewswire.com
Topics Death
Exposures Death
Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations
Via Benzinga
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
Via Benzinga
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
Via Newsfile
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Via Newsfile
Sidoti's Micro-Cap Virtual May Conference
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.